Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Developing Potency-Correlated NAb Assays for AAV5-based Hemophilia Gene Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Developing Potency-Correlated NAb Assays for AAV5-based Hemophilia Gene Therapies

CELL & GENE | RNA | BIOLOGICS

What is the primary challenge in developing a neutralizing antibody (NAb) assay for an AAV5 vector targeting hemophilia?

The central challenge is ensuring the assay possesses functional relevance. A simple binding assay is insufficient. For AAV5-based hemophilia therapies, which target hepatocytes to restore Factor VIII or Factor IX expression, the NAb assay must demonstrate a direct correlation between antibody presence and the inhibition of functional protein expression in a relevant in vitro system. This requires a validated, cell-based assay that accurately reflects the in vivo mechanism of neutralization.

How is the statistical cut point for an AAV5 NAb assay established under GxP?

The cut point is determined by analyzing the NAb signal from a statistically significant number of seronegative, disease-state-relevant individual donors (e.g., hemophilia patient plasma). The process involves establishing a screening cut point, a confirmatory cut point, and often a titration cut point to quantify the NAb titer. Factors like matrix interference and non-specific binding are rigorously evaluated to ensure the assay’s specificity and sensitivity.

Why is a competitive ligand binding (CLB) assay format generally not sufficient for AAV NAb characterization?

While CLB assays can detect antibodies that block the vector from binding to a specific receptor, they do not capture the full spectrum of neutralization mechanisms. Neutralizing antibodies can act at multiple stages post-receptor binding, including interfering with cellular uptake, intracellular trafficking, or uncoating. A cell-based functional assay is required by regulators to measure the ultimate outcome: the inhibition of transgene expression, which provides a more accurate assessment of clinical risk.

Developing a robust neutralizing antibody (NAb) assay for an Adeno-Associated Virus serotype 5 (AAV5) gene therapy requires a cell-based, potency-correlated format. This approach is necessary to accurately quantify the impact of pre-existing or treatment-emergent antibodies on transgene expression, a key risk factor for clinical efficacy in hemophilia programs. Franklin Biolabs develops and validates functional NAb assays that directly measure the inhibition of transgene product, providing precise immunogenicity data to support programs from preclinical assessment through an 18-24 month IND timeline.

The Requirement for Functional NAb Data in AAV5 Programs

For AAV5-based gene therapies targeting hemophilia, the primary mechanism of action relies on efficient hepatocyte transduction and sustained expression of a functional transgene. The presence of neutralizing antibodies can abrogate this effect, representing a significant clinical risk. Consequently, regulatory bodies expect a comprehensive immunogenicity risk assessment built upon an assay that measures functional neutralization, not just antibody binding.

Key considerations for developing a potency-correlated NAb assay include:

  • Assay Format: A cell-based format using a reporter gene (e.g., luciferase) is the standard. This allows for a direct measurement of how antibodies in a sample inhibit the vector’s ability to transduce cells and express its payload.

  • Matrix Specificity: The assay must be validated to perform reliably in the target patient matrix, typically human plasma from individuals with hemophilia, accounting for potential interferences.

  • Vector Characterization: A well-characterized AAV5 reference vector is fundamental to ensuring assay consistency, reproducibility, and accuracy over the lifecycle of the program.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Strategic Assay Design and Validation

A tiered approach to immunogenicity testing is the accepted framework. This begins with a sensitive screening assay to identify potentially positive samples, followed by a confirmatory assay, and finally, a titration assay to quantify the NAb titer in confirmed positive samples. Our approach provides the Immunogenicity Intelligence for Advanced Therapies needed to de-risk clinical translation.

<a href=”

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

Responsible Development and Regulatory Alignment

The successful clinical translation of AAV gene therapies depends on a deep understanding of potential risks. As noted in recent scientific commentary, responsible development must continue by generating robust data to mitigate safety concerns (PMID: 40643951). A validated, potency-correlated NAb assay is a cornerstone of this principle. It provides clear, functional data that informs patient screening, defines eligibility criteria, and helps interpret clinical outcomes. This level of bioanalytical rigor, conducted within our >100,000 sq ft GxP-compliant facility, directly supports regulatory submissions and demonstrates a proactive approach to managing immunogenicity risk.

” ]

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities